Universe Pharmaceuticals INC
UPC Nasdaq Pharmaceutical Preparations Financials FY2019โFY2025
Revenue
Total sales reported in the income statement.
$17.9B
22.4%
vs prior year
Operating margin
Operating income as a share of revenue.
โ16.3%
18.5ย pts
Net income
Profit after all expenses, interest and tax.
โ$3.7B
Free cash flow
Cash from operations minus capital spending.
โ$5.3B
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ7.2%
21.7ย pts
Market cap
Last close times the latest diluted share count, so it is approximate.
โ
P/E
Last close divided by diluted earnings per share over the last four quarters.
โ
On โ$8.06 EPS (TTM)
What Universe Pharmaceuticals INC does
No business description yet.
- Legal name
- Universe Pharmaceuticals INC
- Fiscal year ends
- September 30, 2025
- Latest annual report
- 20-F ยท Jan 29, 2026
- Accession ยท CIK
- 0001213900-26-009000
0001809616
Revenue and margins
Universe Pharmaceuticals INC had $17.9B of revenue in fiscal 2025, down 22.4% on the year before.
FY19
Revenue $33.2M
FY20
Revenue $30.7M
FY21
Revenue $48.0M
FY22
Revenue $40.1M
FY23
Revenue $32.3B
FY24
Revenue $23.0B
FY25
Revenue $17.9B
FY19
Gross 40.3%
Operating 29.4%
Net 22.7%
FCF 39.5%
FY20
Gross 45.9%
Operating 33.4%
Net 24.6%
FCF 19.7%
FY21
Gross 52.8%
Operating 28.3%
Net 23.6%
FCF โ5.2%
FY22
Gross 54.5%
Operating โ17.5%
Net โ19.7%
FCF โ3.5%
FY23
Gross 31.9%
Operating โ12.3%
Net โ20.4%
FCF 3.3%
FY24
Gross 26.4%
Operating โ34.8%
Net โ37.9%
FCF โ42.2%
FY25
Gross 35.3%
Operating โ16.3%
Net โ20.6%
FCF โ29.8%
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY19
Net income $7.6M
FY20
Net income $7.6M
FY21
Net income $11.3M
FY22
Net income โ$7.9M
FY23
Net income โ$6.6B
FY24
Net income โ$8.7B
FY25
Net income โ$3.7B
FY19
Diluted EPS $0.47
FY20
Diluted EPS $0.47
FY21
Diluted EPS $3.58
FY22
Diluted EPS โ$1,309.11
FY23
Diluted EPS โ$1,089.21
FY24
Diluted EPS โ$626.96
FY25
Diluted EPS โ$8.06
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY19
Return on capital โ
Return on equity 61.0%
Return on assets โ
FY20
Return on capital 57.3%
Return on equity 45.5%
Return on assets 26.2%
FY21
Return on capital 38.1%
Return on equity 33.4%
Return on assets 22.9%
FY22
Return on capital โ0.0%
Return on equity โ0.0%
Return on assets โ12.2%
FY23
Return on capital โ13.8%
Return on equity โ20.8%
Return on assets โ12,997.7%
FY24
Return on capital โ29.0%
Return on equity โ23.8%
Return on assets โ25.7%
FY25
Return on capital โ7.2%
Return on equity โ7.2%
Return on assets โ5.4%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was โ$5.3B in fiscal 2025, โ29.8% of revenue. Cash from operations minus capital spending.
FY19
Free cash flow $13.1M
FY20
Free cash flow $6.1M
FY21
Free cash flow โ$2.5M
FY22
Free cash flow โ$1.4M
FY23
Free cash flow $1.1B
FY24
Free cash flow โ$9.7B
FY25
Free cash flow โ$5.3B
FY19
Cash from operations $13.2M
Capital spending $0.1M
FY20
Cash from operations $6.1M
Capital spending $0.1M
FY21
Cash from operations โ$2.1M
Capital spending $0.4M
FY22
Cash from operations โ$1.3M
Capital spending $0.1M
FY23
Cash from operations $1.1B
Capital spending $44.2M
FY24
Cash from operations โ$9.5B
Capital spending $208M
FY25
Cash from operations โ$5.1B
Capital spending $267M
Cash from operations
Capital spending
Dividends, buybacks and share count
Universe Pharmaceuticals INC returned โ to shareholders in fiscal 2025. The diluted share count rose 3,179.9%.
FY19
Dividends $16.0M
Buybacks โ
FY20
Dividends โ
Buybacks โ
FY21
Dividends โ
Buybacks โ
FY22
Dividends โ
Buybacks โ
FY23
Dividends โ
Buybacks โ
FY24
Dividends โ
Buybacks โ
FY25
Dividends โ
Buybacks โ
Dividends
Buybacks
FY19
Diluted shares 0.02B
FY20
Diluted shares 0.02B
FY21
Diluted shares 0.00B
FY22
Diluted shares 0.00B
FY23
Diluted shares 0.00B
FY24
Diluted shares 0.00B
FY25
Diluted shares 0.00B
Balance sheet
Cash, debt and the ratios that show how comfortably Universe Pharmaceuticals INC can carry it.
FY19
Cash $3.2M
Debt โ
FY20
Cash $10.1M
Debt $2.6M
FY21
Cash $21.8M
Debt $4.3M
FY22
Cash $5.7B
Debt $3.9M
FY23
Cash $5.3B
Debt $5.5M
FY24
Cash $29.5B
Debt $5.9B
FY25
Cash $33.6B
Debt $9.3B
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $21.8M | $5.7B | $5.3B | $29.5B | $33.6B |
| Debt incl. finance leases | $4.3M | $3.9M | $5.5M | $5.9B | $9.3B |
| Net debt / EBITDA | โ1.2x | โ | โ | โ | โ |
| Debt / equity | 0.1x | 0.0x | 0.0x | 0.1x | 0.2x |
| Interest coverage | 133.8x | โ43.2x | โ20.9x | โ26.3x | โ10.1x |
| Current ratio | 4.5x | 3.2x | 1.8x | 2.5x | 4.1x |
| Quick ratio | 4.3x | 3.0x | 1.6x | 2.5x | 3.9x |
| Total assets | $70.1M | $59.5M | $41.7M | $68.0B | $69.3B |
| Total liabilities | $23.2M | โ$35.3B | $13.8M | $22.5B | $13.2B |
| Shareholders' equity | $47.0M | $35.3B | $28.0B | $45.5B | $56.1B |
| Net debt (โ = net cash) | โ$17.5M | โ$5.7B | โ$5.3B | โ$23.6B | โ$24.3B |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 5 | 5 / 9 | 3 / 9 | 4 / 9 | 3 / 9 | 3 / 9 |
| Accruals ratio | โ | 5.0% | 27.0% | โ10.2% | โ15,203.4% | 2.3% | 2.0% |
| Altman Z'' | โ | 10.16 | 8.27 | โ | 1,498.17 | 3.87 | 7.37 |
7 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $33.2M | $30.7M | $48.0M | $40.1M | $32.3B | $23.0B | $17.9B |
| Gross profit | $13.4M | $14.1M | $25.3M | $21.9M | $10.3B | $6.1B | $6.3B |
| Research and development | $0.6M | $0.6M | $5.5M | $7.6M | $4.9B | $3.0B | $672M |
| Operating income | $9.8M | $10.3M | $13.6M | โ$7.0M | โ$4.0B | โ$8.0B | โ$2.9B |
| Interest expense | $0.1M | $0.1M | $0.1M | $0.2M | $190M | $305M | $289M |
| Pretax income | $9.7M | $10.1M | $13.7M | โ$7.1M | โ$4.3B | โ$8.1B | โ$3.7B |
| Income tax | $2.1M | $2.5M | $2.4M | $0.8M | $2.3B | $607M | โ |
| Net income | $7.6M | $7.6M | $11.3M | โ$7.9M | โ$6.6B | โ$8.7B | โ$3.7B |
| Diluted EPS | $0.47 | $0.47 | $3.58 | โ$1,309.11 | โ$1,089.21 | โ$626.96 | โ$8.06 |
| Diluted shares | 0.02B | 0.02B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| Cash flow | |||||||
| Cash from operations | $13.2M | $6.1M | โ$2.1M | โ$1.3M | $1.1B | โ$9.5B | โ$5.1B |
| Capital expenditure | $0.1M | $0.1M | $0.4M | $0.1M | $44.2M | $208M | $267M |
| Free cash flow | $13.1M | $6.1M | โ$2.5M | โ$1.4M | $1.1B | โ$9.7B | โ$5.3B |
| Depreciation and amortization | $0.4M | $0.4M | $0.4M | $0.5M | $509M | $486M | $517M |
| Dividends paid | $16.0M | โ | โ | โ | โ | โ | โ |
| Dividends and buybacks | $16.0M | โ | โ | โ | โ | โ | โ |
| Balance sheet | |||||||
| Cash and short-term investments | $3.2M | $10.1M | $21.8M | $5.7B | $5.3B | $29.5B | $33.6B |
| Total debt | โ | $2.6M | $4.3M | $3.9M | $5.5M | $5.9B | $9.3B |
| Current assets | โ | $23.3M | $50.5M | $41.5M | $25.3M | $51.6B | $53.6B |
| Current liabilities | โ | $8.0M | $11.2M | $13.1M | $13.8M | $20.3B | $13.2B |
| Inventory | โ | $1.9M | $2.5M | $2.2M | $3.3M | $1.7B | $2.2B |
| Property and equipment, net | โ | $4.4M | $4.7M | $4.3M | $3.7M | $3.6B | $3.6B |
| Intangible assets | โ | $0.2M | $0.1M | $0.2M | $0.1M | $263M | $297M |
| Total assets | โ | $28.8M | $70.1M | $59.5M | $41.7M | $68.0B | $69.3B |
| Total liabilities | โ | $8.0M | $23.2M | โ$35.3B | $13.8M | $22.5B | $13.2B |
| Shareholders' equity | $12.4M | $20.8M | $47.0M | $35.3B | $28.0B | $45.5B | $56.1B |
| Margins | |||||||
| Gross margin | 40.3% | 45.9% | 52.8% | 54.5% | 31.9% | 26.4% | 35.3% |
| Operating margin | 29.4% | 33.4% | 28.3% | โ17.5% | โ12.3% | โ34.8% | โ16.3% |
| EBITDA margin | 30.6% | 34.7% | 29.3% | โ16.2% | โ10.7% | โ32.7% | โ13.4% |
| Net margin | 22.7% | 24.6% | 23.6% | โ19.7% | โ20.4% | โ37.9% | โ20.6% |
| FCF margin | 39.5% | 19.7% | โ5.2% | โ3.5% | 3.3% | โ42.2% | โ29.8% |
| Returns | |||||||
| Return on capital | โ | 57.3% | 38.1% | โ0.0% | โ13.8% | โ29.0% | โ7.2% |
| Return on capital employed | โ | 49.3% | 23.1% | โ15.1% | โ14,179.7% | โ16.8% | โ5.2% |
| Return on equity | 61.0% | 45.5% | 33.4% | โ0.0% | โ20.8% | โ23.8% | โ7.2% |
| Return on assets | โ | 26.2% | 22.9% | โ12.2% | โ12,997.7% | โ25.7% | โ5.4% |
| Return on tangible equity | 61.0% | 36.6% | 24.2% | โ0.0% | โ23.5% | โ19.3% | โ6.6% |
| Growth | |||||||
| Revenue growth | โ | โ7.6% | 56.3% | โ16.3% | 80,383.7% | โ28.7% | โ22.4% |
| Net income growth | โ | 0.1% | 49.8% | โ169.9% | โ | โ | โ |
| EPS growth | โ | 0.0% | 661.7% | โ36,667.3% | โ | โ | โ |
| FCF growth | โ | โ53.8% | โ141.2% | โ | โ | โ1,005.7% | โ |
| Share count change | โ | 0.0% | โ80.2% | โ99.8% | 0.0% | 131.7% | 3,179.9% |
| Financial health | |||||||
| Net debt / EBITDA | โ | โ0.7x | โ1.2x | โ | โ | โ | โ |
| Debt / equity | โ | 0.1x | 0.1x | 0.0x | 0.0x | 0.1x | 0.2x |
| Interest coverage | 75.4x | 82.8x | 133.8x | โ43.2x | โ20.9x | โ26.3x | โ10.1x |
| Current ratio | โ | 2.9x | 4.5x | 3.2x | 1.8x | 2.5x | 4.1x |
| Quick ratio | โ | 2.7x | 4.3x | 3.0x | 1.6x | 2.5x | 3.9x |
| Capital allocation | |||||||
| Capex / revenue | 0.3% | 0.2% | 0.9% | 0.2% | 0.1% | 0.9% | 1.5% |
| Payouts / FCF | 122.0% | โ | โ | โ | โ | โ | โ |
| Quality scores | |||||||
| Piotroski F-score | โ | โ | 5.0 | 3.0 | 4.0 | 3.0 | 3.0 |
| Altman Z'' | โ | 10.2 | 8.3 | โ | 1,498.2 | 3.9 | 7.4 |
| Accruals ratio | โ | 5.0% | 27.0% | โ10.2% | โ15,203.4% | 2.3% | 2.0% |
Source: SEC EDGAR XBRL filings (CIK 0001809616). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.